update desk

Israeli hospital claims it has developed drug to cure serious cases of COVID

According to its staff, 29 out of 30 patients with moderate-to-severe cases of the coronavirus were administered EXO-CD24 and experienced a marked recovery in just two days.

Staff in the coronavirus ward of Ichilov Hospital, Tel Aviv Sourasky Medical Center, on Jan. 1, 2021. Photo by Tomer Neuberg/Flash90.
Staff in the coronavirus ward of Ichilov Hospital, Tel Aviv Sourasky Medical Center, on Jan. 1, 2021. Photo by Tomer Neuberg/Flash90.

Researchers at Israel’s Ichilov Hospital, Tel Aviv Sourasky Medical Center claim that they have developed a drug that may cure serious cases of the coronavirus.

According to the hospital, 29 out of 30 patients with moderate-to-severe cases of COVID-19 were administered the drug, named EXO-CD24, and experienced a marked recovery in just two days. They were released from the hospital three to five days later.

The medication, developed by Professor Nadir Arber from the hospital’s Integrated Cancer Prevention Center, fights the cytokine storm—is a potentially life-threatening systemic inflammatory syndrome that is believed to be responsible for many coronavirus deaths.

“The medicine is administered through inhalation, once a day, in a procedure that takes only a few minutes, for five days,” explained Arber.

“It is based on exosomes that the body is releasing from the cell membrane and uses for intercellular communication. We enrich the exosomes with the 24CD protein, which is known to play an important role in regulating the immune system,” according to Arber’s director of laboratory Dr. Shiran Shapira, who has been conducting research on CD24 protein for decades.

The medicine will now move on to additional trial phases, though the hospital sees it as a potential game-changer.

“I’m proud that here at Ichilov we are among the world leaders in finding the cure for the horrible epidemic,” said Professor Roni Gamzu, CEO of Ichilov Hospital and Israel’s former coronavirus czar.

You have read 3 articles this month.
Register to receive full access to JNS.

Just before you scroll on...

Israel is at war. JNS is combating the stream of misinformation on Israel with real, honest and factual reporting. In order to deliver this in-depth, unbiased coverage of Israel and the Jewish world, we rely on readers like you. The support you provide allows our journalists to deliver the truth, free from bias and hidden agendas. Can we count on your support? Every contribution, big or small, helps JNS.org remain a trusted source of news you can rely on.

Become a part of our mission by donating today
Topics
Comments
Thank you. You are a loyal JNS Reader.
You have read more than 10 articles this month.
Please register for full access to continue reading and post comments.
Never miss a thing
Get the best stories faster with JNS breaking news updates